Healthcare Sector: New Share Price Targets Issued

Wall St. Watchdog reveals information about companies for which stock analysts reiterated ratings in the Healthcare sector for the week ending November 4th, 2011.

  • Biogen Idec (NASDAQ:BIIB): UBS reiterated its rating of Buy for this company and changed its price target from $113 to $132 on Oct 31st. The shares recently traded at $114.01, down $2.35, or 2.02% since the analyst’s rating. About the company: Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis. Get the most recent company news and stock data here >>
  • Biomarin Pharm (NASDAQ:BMRN): Summer Street Research reiterated its rating of Buy for this company and changed its price target from $32 to $40 on Oct 31st. The shares recently traded at $32.54, down $1.57, or 4.6% since the analyst’s rating. About the company: BioMarin Pharmaceutical Inc. develops and commercializes therapeutic enzyme products. The Company has applied its proprietary enzyme technology to develop products for lysosomal storage diseases and for the treatment of serious burns. BioMarin’s subsidiary provides analytical and diagnostic products and services in the area of carbohydrate biology. Get the most recent company news and stock data here >>
  • Humana (NYSE:HUM): UBS reiterated its rating of Buy for this company and changed its price target from $87 to $95 on Nov 1st. The shares recently traded at $87.15, up $3.39, or 4.05% since the analyst’s rating. About the company: Humana Inc. is a managed health care company with medical members located in the United States and Puerto Rico. The Company offers coordinated health care through health maintenance organizations, preferred provider organizations, point-of-service plans, and administrative services products. Humana offers its products to employer groups, government-sponsored plans, and individuals. Get the most recent company news and stock data here >>
  • Auxilium Pharma (NASDAQ:AUXL): UBS reiterated its rating of Buy for this company and changed its price target from $30 to $27 on Nov 1st. The shares recently traded at $15.21, up $0.09, or 0.6% since the analyst’s rating. About the company: Auxilium Pharmaceuticals Inc. is a biopharmaceutical company . The Company develops and markets therapeutics to urologists, endocrinologists, orthopedists and select primary care physicians. Get the most recent company news and stock data here >>
  • Neurogesx (NASDAQ:NGSX): Ladenburg Thalmann reiterated its rating of Buy for this company and changed its price target from $5 to $2.5 on Nov 1st. The shares recently traded at $1.23, up $0.13, or 11.82% since the analyst’s rating. About the company: NeurogesX, Inc. is a biopharmaceutical company. The Company develops treatments for chronic peripheral neuropathic pain including postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Get the most recent company news and stock data here >>
  • Integra (NASDAQ:IART): RBC Capital Mkts reiterated its rating of Sector Perform for this company and changed its price target from $43 to $40 on Nov 1st. The shares recently traded at $30.40, up $0.4, or 1.33% since the analyst’s rating. About the company: Integra LifeSciences Holdings develops, manufactures, and markets medical devices, implants, and biomaterials. The Company’s products are primarily used in the treatment of burns and skin defects, spinal and cranial disorders, orthopedics, and other surgical applications. Get the most recent company news and stock data here >>
  • Celldex Therapeutics (NASDAQ:CLDX): Brean Murray reiterated its rating of Buy for this company and changed its price target from $16 to $14 on Nov 2nd. The shares recently traded at $2.89, down $0.16, or 5.25% since the analyst’s rating. About the company: Celldex Therapeutics Inc., a biopharmaceutical company, uses applications of immunology to prevent and treat diseases. The Company’s products treat autoimmune diseases, cardiovascular diseases, cancer, and inflammation, as well as infectious diseases and organ transplant rejection. Get the most recent company news and stock data here >>
  • Teva Pharma (NASDAQ:TEVA): UBS reiterated its rating of Buy for this company and changed its price target from $64 to $60. Needham reiterated its rating of Strong Buy for this company and changed its price target from $58 to $56 on Nov 3rd. The shares recently traded at $41.72, down $0.08, or 0.19% since the analyst’s rating. About the company: Teva Pharmaceutical Industries Ltd. develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. The Company produces antibiotics, oncological products, Alpha D3 for treatment of post-menopausal bone loss in women and Copaxone for treatment of multiple sclerosis. Teva develops novel drugs for diseases of the central nervous system. Get the most recent company news and stock data here >>
  • Steris (NYSE:STE): JMP Securities reiterated its rating of Mkt Outperform for this company and changed its price target from $39 to $37 on Nov 3rd. The shares recently traded at $29.17, up $0.29, or 1% since the analyst’s rating. About the company: STERIS Corporation provides sterilization, microbial reduction, and materials modification services to customers throughout the world. The Company’s customers include the medical device, pharmaceutical, biotechnology, food safety, and industrial markets. STERIS also markets a line of cleaning, decontamination, and sterilization systems, products, and technologies. Get the most recent company news and stock data here >>
  • Hologic (NASDAQ:HOLX): Stifel Nicolaus reiterated its rating of Buy for this company and changed its price target from $23 to $20 on Nov 3rd. The shares recently traded at $16.23, up $0.07, or 0.43% since the analyst’s rating. About the company: Hologic, Inc. develops, manufactures, and markets x-ray systems. The Company makes x-ray bone densitometers that measure the precise bone density for use in the diagnosing of metabolic bone diseases such as osteoporosis. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet